Nevro (NYSE:NVRO) is scheduled to be announcing its earnings results after the market closes on Thursday, February 22nd. Analysts expect the company to announce earnings of ($0.14) per share for the quarter.
Shares of Nevro (NYSE NVRO) opened at $77.30 on Thursday. The company has a debt-to-equity ratio of 0.59, a current ratio of 8.78 and a quick ratio of 6.81. Nevro has a 1 year low of $65.00 and a 1 year high of $99.63. The company has a market cap of $2,290.00, a price-to-earnings ratio of -53.31 and a beta of -0.59.
A number of analysts recently commented on NVRO shares. Northland Securities restated a “buy” rating and issued a $96.00 price objective on shares of Nevro in a research report on Tuesday, November 7th. BidaskClub cut shares of Nevro from a “sell” rating to a “strong sell” rating in a research report on Tuesday, November 14th. ValuEngine cut shares of Nevro from a “hold” rating to a “sell” rating in a research report on Friday, February 2nd. Canaccord Genuity lowered their price objective on shares of Nevro from $120.00 to $110.00 and set a “buy” rating for the company in a research report on Tuesday, November 7th. Finally, TheStreet upgraded shares of Nevro from a “d+” rating to a “c-” rating in a research report on Monday, November 6th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $99.25.
COPYRIGHT VIOLATION NOTICE: This news story was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://www.americanbankingnews.com/2018/02/15/nevro-nvro-scheduled-to-post-quarterly-earnings-on-thursday.html.
Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.
Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.